This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
The Zacks Analyst Blog Highlights: Walmart, AstraZeneca, HSBC Holdings, Exxon Mobil and Altria Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, AstraZeneca, HSBC Holdings, Exxon Mobil and Altria Group
Top Analyst Reports for Walmart, AstraZeneca & HSBC
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), AstraZeneca (AZN) and HSBC Holdings (HSBC).
Altria's (MO) Q3 Earnings Surpass Estimates on Solid Pricing
by Zacks Equity Research
Altria's (MO) third-quarter 2020 results reflect strong pricing in smokeable and oral tobacco product segments. Management lifts the lower end of its previously guided earnings view.
Altria (MO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 3.48% and 2.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Altria (MO) Might Surprise This Earnings Season
by Zacks Equity Research
Altria (MO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Altria (MO) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Altria's (MO) third-quarter 2020 results are likely to reflect gains from pricing and strength in oral tobacco products. However, cigarette volumes have been soft for a while.
Altria (MO) Stock Moves -1.31%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $38.57 in the latest trading session, marking a -1.31% move from the prior day.
Altria (MO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What You Should Know Ahead of FEMSA's (FMX) Q3 Earnings
by Zacks Equity Research
FEMSA (FMX) has been witnessing softness across all segments, owing to the coronavirus-led restrictions, which are likely to have resulted in reduced traffic trends in the third quarter.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $38.70, moving -1.23% from the previous trading session.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $39.55 in the latest trading session, marking a +0.43% move from the prior day.
Why Altria (MO) Could Beat Earnings Estimates Again
by Zacks Equity Research
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: Adobe, Costco, Union Pacific, NextEra Energy and Altria Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Adobe, Costco, Union Pacific, NextEra Energy and Altria Group
Top Stock Reports for Adobe, Costco & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Costco Wholesale (COST) and Union Pacific (UNP).
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $39.50, moving +1.36% from the previous trading session.
Altria (MO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $38.36, moving -1.51% from the previous trading session.
Oral Tobacco Unit Supports Altria Amid Poor Cigarette Sales
by Zacks Equity Research
Altria (MO) is gaining from rising popularity of low risk tobacco alternatives. However the company's smokeable unit is bearing the brunt of soft cigarette sales.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $38.55, moving -0.7% from the previous trading session.
RRPs a Respite for Philip Morris Amid Low Cigarette Sales
by Zacks Equity Research
Philip Morris (PM) is gaining from growing popularity of IQOS. However, low cigarette sales is a dampener.
4 Tobacco Stocks to Watch Amid Rising Popularity of RRPs
by Zacks Equity Research
Zacks Tobacco industry players like PM, MO, VGR and TPB are poised to benefit from rising popularity of low risk tobacco alternatives such as e-cigarettes and vaping products. However, low cigarette sales volumes are likely to remain a worry.
4 Tobacco Stocks to Watch Amid Rising Popularity of RRPs
by Zacks Equity Research
Zacks Tobacco industry players like PM, MO, VGR and TPB are poised to benefit from rising popularity of low risk tobacco alternatives such as e-cigarettes and vaping products. However, low cigarette sales volumes are likely to remain a worry.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $43 in the latest trading session, marking a -1.35% move from the prior day.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $43.49, marking a +0.46% move from the previous day.
Altria (MO) Up 3.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Altria Gains From Oral Products Amid Lower Cigarette Sales
by Zacks Equity Research
Despite dismal cigarette sales, pricing power and growth in oral tobacco are offering Altria (MO) some respite.